Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion

GSK

  • GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs

    April 30, 2025

    British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]

  • As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers?

    April 22, 2025

    For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.  The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]

  • Government scrambles to swerve Trump pharma tariffs

    April 16, 2025

    A race against time is underway to shield the UK pharmaceutical sector from potentially swinging Trump tariffs on imported drugs.  As it stands, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming into the US.  However, President Trump has warned that there will be tariffs on imported pharma [...]

  • FTSE 100 slumps as EU and China launch retaliatory tariffs against US

    April 9, 2025

    The FTSE 100 closed in the red on Wednesday, reversing gains made at the start of the week. The blue-chip index was off 2.9 per cent. Pharma stocks drove losses on the back of fresh tariff threats from President Donald Trump. Astrazeneca closed off seven per cent and GSK 5.7 per cent. Lenders also suffered [...]

  • JD Sports, Dr Martens and miners: UK stocks hit by Trump tariffs

    April 3, 2025

    UK markets have been pummelled by US president Donald Trump’s newly-introduced tariffs, with JD Sports and miners hit particularly hard on the FTSE 100. JD Sports has been pushing a rapid expansion into the US, which is now its largest region by revenue, but is set to be hit by the 10 per cent tariff [...]

  • FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs

    April 3, 2025

    FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the [...]

  • Mark Kleinman: Football watchdog search approaches injury time

    March 6, 2025

    Mark Kleinman is Sky News’ City Editor and the man who gets the Square Mile talking in his weekly City PM column. Today, he tackles the football watchdog search, big pay at GSK and CityFibre’s M&A warchest Football watchdog search approaches final whistle They think it’s all over. To paraphrase the immortal line of Kenneth Wolstenholme, the 1966 World [...]

  • FTSE 100 giant GSK eyes more than £40bn in sales by 2031

    February 5, 2025

    Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]

  • GSK: Zantac settlements hit profit but guidance unchanged

    October 30, 2024

    Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose [...]

  • GSK shares rise after £1.7bn Zantac settlement

    October 10, 2024

    GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]

Posts pagination

  • Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 22
  • Next

Trending Articles

  • Reeves’ new tax charge on cash ISAs faces fierce industry backlash

  • As it happened: Stocks recover after markets rocked by tech-sell off; US claims ‘good foundations’ of Iran deal

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • As it happened: FTSE 100 scrapes into green after Segro’s surge; Oil at pre-war levels after Trump snaps at industry

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM. All rights reserved.
About · Contact · Terms · Privacy